Article
The evaluation of quinonoid compounds against Trypanosoma cruzi: synthesis of imidazolic anthraquinones, nor-beta-lapachone derivatives and beta-lapachone-based 1,2,3-triazoles
Registro en:
SILVA JÚNIOR, Eufrânio N. da; et al. The evaluation of quinonoid compounds against Trypanosoma cruzi: Synthesis of imidazolic anthraquinones, nor-b-lapachone derivatives and b-lapachone-based 1,2,3-triazoles. Bioorganic & Medicinal Chemistry, v.18, p.3224–3230, 2010.
0968-0896
10.1016/j.bmc.2010.03.029
1464-3391
Autor
Silva, Eufrânio N. da
Guimarães, Tiago T.
Menna-Barreto, Rubem F. S.
Pinto, Maria do Carmo F. R.
Simone, Carlos A. de
Pessoa, Claudia
Cavalcanti, Bruno C.
Sabino, José R.
Andrade, Carlos Kleber Z.
Goulart, Marilia O. F.
Castro, Solange L. de
Pinto, Antônio V.
Resumen
In continuing our screening program of naphthoquinone activity against Trypanosoma cruzi, the aetiological agent of Chagas' disease, new beta-lapachone-based 1,2,3-triazoles, 3-arylamino-nor-beta-lapachones, 3-alkoxy-nor-beta-lapachones and imidazole anthraquinones were synthesised and evaluated against bloodstream trypomastigote forms of the parasite. Compounds 2,2-dimethyl-3-(2,4-dibromophenylamino)-2,3-dihydro-naphtho[1,2-b]furan-4,5-dione, IC(50)/24h 24.9+/-7.4 and 4-azido-3-bromo-2,2-dimethyl-3,4-dihydro-2H-benzo[h]chromene-5,6-dione with 23.4+/-3.8 microM showed a trypanosomicidal activity higher than benznidazole. These results demonstrate the potential of naphthoquinone derivatives as novel structures for the development of alternative drugs for Chagas' disease. 2030-01-01